Great progress had been made in the fight against COVID-19. To date, 32.9% of the world’s population is at least partially vaccinated. Still, the global community has a long way to go before everyone is protected. Continuing to prioritize and support innovation to identify effective treatments, vaccines or boosters, and furthering our understanding of variants, remains critical to the global response.
Breakthrough treatments and increased access to health care are helping people across Southeast Asia live longer than ever before. While the COVID-19 pandemic has brought new attention and respect for innovative treatments and medicines, more needs to be done to deploy novel therapeutics to combat longstanding challenges. For example, in 2016, the World Health Organization (WHO) declared non-communicable diseases (NCDs) – including cancer, diabetes, chronic respiratory conditions and cardiovascular diseases – the leading cause of death in Southeast Asia.
Since the beginning of the COVID-19 pandemic, biopharmaceutical companies have found innovative ways to combat the global health crisis through unprecedented collaboration and partnerships, strengthened intellectual property rights and advanced research and development (R&D) processes. Innovators responded quickly by leveraging decades of existing research and scientific knowledge and building a robust innovation ecosystem that have since lead to several approved COVID-19 vaccines and treatments. As distribution continues to ramp up, patients throughout Southeast Asia are feeling the benefits of this biopharmaceutical investment and innovation.
Over the past year, biopharmaceutical companies have worked at an unprecedented speed to research and develop COVID-19 vaccines, treatments and diagnostics – supported by the innovation ecosystem along the way. As regulatory authorities continue to monitor the safety and efficacy of these innovations and authorize them for public use, it is important for patients to also feel confident in and accept inoculation once vaccine supply is available.
Explore the Countries
Indonesia has achieved significant health milestones, but rising rates of NCDs bring new challenges.
Malaysia can attract new foreign investment and improve health outcomes by better protecting innovation and reducing bureaucratic delays.
Increasing public-private partnerships in the Philippines will bring health care innovation to a rapidly growing population
Health care is poised to become a major economic driver in Thailand in the coming years.
The success of Singapore’s health care system can be attributed to strong policies and an integrated health system.